We have previously demonstrated that inhibiting CatS from birth in an in vivo model of CF-like lung disease reduces pulmonary inflammation, airway mucus obstruction, and lung tissue destruction via a mechanism that is mediated, in part, via protease activated receptor-2 [27]. Here, PIMREG is linked to cystic fibrosis.